NMRA Neumora Therapeutics, Inc.
Company Analysis
Latest News
🟢 Neumora Therapeutics rises 5.9% — Biotech Sector Continues Upward Trend on Strong Momentum
With Biotech (XBI) up 2.0%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 Neumora Therapeutics falls 5.2% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Neumora Therapeutics is trading 5.59% up today without a confirmed catalyst
Neumora Therapeutics is trading 5.59% up at $1.60 despite broader market weakness on August 18, 2026, with no new company-specific announcement clearly...
Neumora Therapeutics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 19, 2026
Neumora Therapeutics is projected to report a Q2 2026 consensus revenue of $0.00 and an EPS loss of -$0.24, with its current price of $1.59 trading...
🔴 Neumora Therapeutics is trading 5.6% down today after August 14 earnings release and leadership transition
Neumora Therapeutics is trading at $1.51 (-5.59%) after investors absorbed its August 14, 2026 earnings release and leadership transition. - Although its...
🔴 Neumora Therapeutics is trading 5% down today after reporting a $43.1 million net loss
Neumora Therapeutics is trading at $1.64, down -5.20%, after reporting second-quarter results and appointing Joshua Pinto as CEO. • Reported a $43.1 million...
Neumora Therapeutics reports second quarter 2026 net loss of $43.1M and names new CEO
Neumora Therapeutics, a clinical-stage biotechnology company, reported a narrowing net loss for the second quarter of 2026 as it reduced operating expenses and...
Neumora Therapeutics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Neumora Therapeutics is expected to report a Q2 2026 loss of $0.23 per share on zero revenue, with its current stock price of $1.64 trading significantly below...
🔴 Neumora Therapeutics is trading 8.2% down today on profit-taking and liquidity-driven trading
Neumora Therapeutics is trading 8.2% down at $1.51 today on profit-taking and liquidity-driven trading following a period of high volatility. • The move...
🔴 Neumora Therapeutics is trading 13.3% down today amid light liquidity and no fresh news
Neumora Therapeutics is trading 13.3% down at $1.43 in thin pre-market action, extending recent volatility after several double-digit daily moves this week. •...
🔴 Neumora Therapeutics is trading 5.5% down today on light pre-market liquidity
Neumora Therapeutics is trading 5.5% down at $1.56 in pre-market sessions, likely reflecting a light-liquidity adjustment in the absence of fresh catalysts. •...
🟢 Neumora Therapeutics is trading 10.4% up today as biotech sector rallies on M&A activity
Neumora Therapeutics is trading 10.4% up at $1.65 as the broader biotech sector rallies on blockbuster M&A activity and positive trial data across the...
🟢 Neumora Therapeutics rises 6.4% — Biotech Sector Rallies on Blockbuster M&A Deal and Positive Trial Data
With Biotech (XBI) up 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
🔴 Neumora Therapeutics, Inc. is trading 5.45% down
NMRA is trading at $1.48, down 5.45%.
🟢 Neumora Therapeutics is trading 5.3% up today as it recovers from Phase 3 depression drug failure
Neumora Therapeutics is trading 5.3% up today at $1.69, staging a modest recovery after sharp losses tied to the recent failure of its lead clinical...
🔴 Neumora Therapeutics is trading 5.1% down today after RBC Capital lowered its price target
• Neumora Therapeutics is trading at $1.59 (-5.06%) after RBC Capital lowered its price target to $5.00 from $7.00. • This downgrade follows the company's...
🟢 Neumora Therapeutics is trading 8.5% up today as it rebounds from a recent trial-related collapse
Neumora Therapeutics is trading at $1.79, up 8.5% in after-hours trading, rebounding from a sharp drop tied to failed Phase 3 trials and a major workforce...
🔴 NMRA extends move to 5.2% down
NMRA is trading at $1.64, down 5.2% versus the comparison close of $1.73 during regular trading. This is a price-movement alert; no separate company-specific...
🔴 NMRA is trading 5.5% down today as shares drift lower following failed Phase 3 trials
NMRA is trading at $1.64 (5.5% down) as shares continue to drift lower following June’s sharp selloff tied to failed Phase 3 KOASTAL trials and the...
🟢 NMRA is trading 5.03% up today on technical rebound amid biotech volatility
NMRA is trading at $1.77 (5.03% up) as the stock stages a technical recovery following a significant June selloff linked to failed Phase 3 KOASTAL trials and...